VIVO - Meridian Bioscience provides preliminary FQ2 numbers

Meridian Bioscience (NASDAQ:VIVO) provided preliminary net revenues for FQ2 are expected to be between $109M and $113M, above company's expectations and a record for the company. Consensus revenue expectation for FQ2 is $83.3M. Individually, both of the company's segments are also expected to have record net revenues in the quarter with the Diagnostics segment net revenues expected to be between $40M-42M and the Life Science segment net revenues expected to be between $69M-71M.   Strong demand for reagents associated with COVID-19 antigen testing during the recent Omicron wave of infections contributed to Life Science segment results. Stock climbs 1% during pre-market

For further details see:

Meridian Bioscience provides preliminary FQ2 numbers